About
Nectin Therapeutics is a biotechnology company devoted to transforming the lives of cancer patients by the development of next-generation immune-oncology (IO) therapies. The company is dedicated to the development of novel therapeutic options for cancer patients. It is developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, it develops CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers. The company was established based on seminal research at the Hebrew University of Jerusalem and the University of Rijeka. Its technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody-drug-conjugates.
Funding history · 6 rounds · $36.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was Nectin Therapeutics founded and what is its primary focus?
- Nectin Therapeutics was founded in January 2017. It is a biotechnology company focused on developing next-generation immune-oncology therapies for cancer patients.
- What was the total amount of funding raised by Nectin Therapeutics as of May 2024?
- As of May 2024, Nectin Therapeutics has raised a total of $36 million across multiple funding rounds.
- Which investors participated in Nectin Therapeutics' Series A funding round in December 2022?
- In December 2022, Nectin Therapeutics raised $13.6 million in a Series A round with lead investors Peregrine Ventures and Israel Biotech Fund, also including aMoon Fund.
- What was the most recent funding round for Nectin Therapeutics and who was the lead investor?
- Nectin Therapeutics completed a Series A funding round in May 2024, raising $10 million. The lead investor was Guangzhou Sino-Israel Biotech Investment Fund (GIBF).
- With which pharmaceutical company did Nectin Therapeutics announce a clinical trial collaboration in February 2023?
- In February 2023, Nectin Therapeutics announced a collaboration with Merck on a clinical trial for its anti-PVR antibody NTX1088 in combination with KEYTRUDA (pembrolizumab) for patients with advanced solid tumors.
- When did Nectin Therapeutics initiate patient dosing for its Phase 1 clinical trial of NTX1088?
- Nectin Therapeutics initiated patient dosing in its Phase 1 clinical trial of NTX1088, an anti-PVR targeted immunotherapy, in November 2022.
- Which fund invested in Nectin Therapeutics in May 2023 to evaluate its anti-PVR lead drug candidate for multiple myeloma?
- In May 2023, the Myeloma Investment Fund invested in Nectin Therapeutics to evaluate its anti-PVR lead drug candidate as a treatment for multiple myeloma.
- Where are Nectin Therapeutics' headquarters located?
- Nectin Therapeutics' headquarters are located in Jerusalem, Israel, with an additional office in Fort Lee, NJ, USA.